Accessibility StatementSkip Navigation RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately. Â Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in servic ...

Accessibility StatementSkip Navigation RADNOR, Pa., Nov. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its newest Centralized Service Center (CSC) serving the Greater Boston area. Avantor® Expands Centralized Service Center Model with Opening of Boston-Area Facility Avantor® Expands Centralized Service Center Model with Opening of Bos ...

Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Date of Conference**: November 18, 2025 - **Focus**: Discussion on financial performance, market trends, and growth opportunities Key Highlights Industry Performance - **Pharma Market**: - Continued strong performance with double-digit growth for three consecutive quarters, contributing approximately 30% of total revenue [2][10] - Recent pricing mechanisms by large pharma have appeased regulatory concerns, leading to a more optimistic outlook [11] - **Spatial Biology Franchise**: - Signs of recovery with low single-digit growth in consumables and double-digit growth in instruments [3][4] - Growth in China noted for the second consecutive quarter, with expectations for continued growth [3][17] - **Biotech Market**: - Despite a 30% year-over-year decline in funding, the market showed resilience with low single-digit growth [10][14] - Recent increases in biotech funding, with October showing an 80% year-over-year growth, indicating potential recovery [15] Financial Performance - **Operating Margins**: - Expanded by 90 basis points despite challenging market conditions, attributed to portfolio management and productivity initiatives [5] - **Customer Dynamics**: - Two major cell therapy customers received FDA Fast-Track designation, which may create short-term headwinds due to reduced material purchases but is expected to enhance long-term growth potential [4][22] Market Trends - **China's Growth**: - Regulatory environment favorable for Bio-Techne, with expectations for China to become a net contributor to growth over the next 12-24 months [17][18] - Local competition exists, but brand strength and product quality remain key differentiators [20][21] - **Cell and Gene Therapy**: - Anticipated headwinds due to customer purchasing dynamics, but long-term growth prospects remain strong with potential revenue from commercialized therapies estimated at $100 million [35][36] Future Outlook - **Growth Projections**: - Confidence in achieving low single-digit organic growth in FY2026 despite near-term challenges, driven by stabilization in pharma and academic markets [58][59] - Long-term potential for double-digit growth as market conditions normalize and cell therapy commercialization ramps up [62][64] Product Development - **Innovations**: - Introduction of advanced instruments and consumables, particularly in the spatial biology and protein sciences segments, expected to drive future growth [54][50] - Ongoing development of AI-generated proteins and integration of new technologies to enhance product offerings [30][40] Additional Insights - **Market Positioning**: - Bio-Techne's focus on quality and consistency in product offerings is crucial for maintaining competitive advantage in both domestic and international markets [20][21] - **Customer Engagement**: - Continuous engagement with customers to understand their needs and preferences is vital for product development and market penetration [20] - **Long-term Strategy**: - The company is positioned to leverage its growth pillars (cell therapy, spatial, ProteinSimple) to exceed market growth rates and achieve sustainable long-term growth [63][64]

Core Insights - Twist Bioscience Corporation reported a mixed performance for the fourth quarter, with a loss of 45 cents per share, slightly worse than the consensus estimate of a 43-cent loss, while sales reached $99.01 million, up 17% year over year, exceeding the consensus of $97.32 million [1][2] Financial Performance - The adjusted EBITDA loss for the fourth quarter was $7.8 million, an improvement from a loss of $17 million a year ago [1] - Gross margin for the fourth quarter increased to 51.3%, compared to 45.1% a year ago [2] Customer and Product Metrics - The company shipped products to approximately 3,800 customers in 2025, up from about 3,550 the previous year [2] - Twist shipped approximately 938,000 genes, an increase from approximately 772,000 genes a year ago [2] Future Outlook - For fiscal 2026, Twist Bioscience expects sales between $425 million and $435 million, significantly higher than the consensus of $374.69 million [3] - The guidance includes revenue expectations of approximately $194 million to $199 million from DNA Synthesis and Protein Solutions, and $231 million to $236 million from NGS Applications [3] - Gross margin is anticipated to be above 52% for fiscal 2026 [3] - For the first quarter of 2026, sales are projected to be between $100 million and $101 million, compared to the consensus of $100.34 million [3] Strategic Goals - The company aims to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026, entering a new growth phase [4] - CEO Emily M. Leproust emphasized the goal of maintaining gross margins above 50% and moving towards sustained profitable growth [4] Analyst Perspective - William Blair noted that shares of Twist trade at 3.9 times its calendar 2026 sales target, below the average of 6.3 times for high-growth life science tools peers [5] - Analyst Matt Larew expressed confidence in the long-term revenue growth trajectory, highlighting the company's aggressive investments in multiple markets, which could lead to over 20% growth [5] - The company’s strategy to moderate investments while aiming for adjusted EBITDA breakeven is seen as a positive move [6]

Accessibility StatementSkip Navigation RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn brings more than three decades of global operations, manufacturing, and supply chain leadersh ...

Core Viewpoint - Charles River Laboratories reported a decline in third-quarter 2025 earnings, leading to a decrease in stock price, while also announcing a strategic review to enhance profitability and efficiency [1][9]. Financial Performance - The company reported quarterly revenue of $1.01 billion, a 0.5% decrease year-over-year, surpassing the consensus estimate of $990.77 million [2]. - Foreign currency translation positively impacted reported revenue by 1.3%, while the divestiture of a small Safety Assessment site reduced revenue by 0.2%. Excluding these effects, organic revenue declined by 1.6% [2]. - Operating margin increased to 13.3% from 11.6%, mainly due to lower costs from restructuring initiatives, while adjusted operating margin slightly decreased to 19.7% from 19.9% [3]. - Adjusted earnings reached $2.43 per share, exceeding the consensus of $2.34 [3]. Segment Performance - Revenue for the Research Models and Services (RMS) segment was $213.5 million, up 7.9% year-over-year, with organic revenue increasing by 6.5% due to higher sales of large research model products [4]. - The Discovery and Safety Assessment (DSA) segment reported revenue of $600.7 million, down 2.3%, with organic revenue decreasing by 3.1% due to lower sales volume [4]. - Manufacturing segment sales were $190.7 million, down 3.1%, with organic revenue decreasing by 5.1%, primarily from lower revenue in CDMO and Biologics Testing businesses [5]. 2025 Outlook - The company expects 2025 revenue to decline between (1.5)% and (0.5)%, with organic revenue down by (2.5)%–(1.5)% [6]. - Sales guidance for 2025 was lowered from $3.95 billion-$4.03 billion to $3.85 billion-$3.99 billion, aligning with the consensus of $3.99 billion [6]. - Adjusted earnings guidance for 2025 was raised from $9.90-$10.30 per share to $10.10-$10.30, compared to the consensus of $10.19 [6]. Strategic Review Update - The company plans to divest certain underperforming assets, which represent approximately 7% of estimated 2025 revenue, to focus on more profitable growth opportunities [7]. - Proposed divestitures are expected to result in non-GAAP earnings per share accretion of at least $0.30 annually [7]. - The company has initiated several restructuring and efficiency measures aimed at protecting margins and reviving earnings in a challenging demand environment [7]. Cost Savings Initiatives - The company anticipates annualized cost savings of about $225 million by 2026 from its restructuring efforts [8]. - Additional measures focusing on process improvements and procurement synergies are projected to yield an extra $70 million in yearly savings, with full realization expected by 2026 [8]. Stock Repurchase Authorization - In October, the company's board approved a new $1 billion stock repurchase authorization [9].

Core Insights - Avantor, Inc. has launched pre-engineered PUPSIT assemblies and a comprehensive sterile sampling suite aimed at enhancing bioprocessing flexibility and reducing contamination risks while accelerating in-process decisions [1][4] Product Features - The sterile sampling suite features modular, multi-sample configurations that minimize line breaks and operator intervention, with standardized bills of materials to streamline setup and qualification [2][3] - PUPSIT assemblies integrate supplier-agnostic components that connect seamlessly with common filtration trains, simplifying implementation and maintaining closed flow paths to reduce setup variability [3][4] Market Needs - Biopharmaceutical manufacturers require configurable and easy-to-implement solutions that perform consistently across different scales, which the new products from Avantor aim to address [5] - The combination of the newly launched NFSS and EVSS with existing products positions Avantor's sampling platform as one of the most comprehensive solutions for bioprocessing sampling applications [5] Company Overview - Avantor is a leading life science tools company providing mission-critical products and services to the life sciences and advanced technology industries, supporting research, development, and production activities globally [6]

Core Insights - Avantor Inc. reported third-quarter 2025 adjusted earnings of 22 cents, below the consensus estimate of 23 cents [1] - The company’s sales were $1.62 billion, slightly missing the consensus of $1.65 billion, with a year-over-year decline of 5.3% [1] - Organic sales declined by 4.7%, impacted by a positive foreign currency translation of 2.2% and a negative M&A impact of 2.8% [1] Segment Performance - Laboratory Solutions sales were $1.09 billion, reflecting a 6.4% decrease, with an organic decline of 4.9% [2] - Bioscience Production sales totaled $527.3 million, down 2.9% reported and 4.3% organically, with operational headwinds affecting throughput [3] Strategic Initiatives - The company announced a $500 million share repurchase authorization, indicating confidence in cash generation and a commitment to long-term shareholder value [4] - CEO Emmanuel Ligner emphasized the need for decisive changes to improve execution, accountability, and financial performance [4] Guidance and Analyst Commentary - Avantor revised its fiscal 2025 adjusted earnings per share guidance from 94-98 cents to 88-92 cents, compared to the consensus of 95 cents [5] - The company expects organic revenue to decline between 3.5% and 2.5%, with an adjusted EBITDA margin in the mid-16% range [5] - Analysts suggest that while there is potential for outperformance, the company's current growth and margin profile justify a discount compared to peers [6]

Accessibility StatementSkip Navigation RADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2025. "Avantor's diverse portfolio, strong production capabilities, and long-standing customer relationships provide a strong foundation for sustained value creation," said Emmanuel ...

Core Points - Gregory L. Summe will become the next Chairman of the Board for Avantor, Inc. starting January 1, 2026, succeeding Jonathan Peacock who will step down at the end of 2025 after nearly nine years of service [1] - Summe has been an independent director since 2020 and has served as Chairman of the Nominating and Governance Committee, as well as a member of the Compensation Committee [2] - Peacock expressed confidence in the new leadership under Summe and CEO Emmanuel Ligner, highlighting the Board's diverse expertise in life sciences [3] Company Overview - Avantor, Inc. is a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, supporting over 300,000 customer locations in 180 countries [4]